No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ELEV Elevation Oncology
- 2.760
- -0.215-7.23%
Close Jun 18 16:00 ET
- 2.750
- -0.010-0.36%
Post 17:15 ET
150.80MMarket Cap-3247P/E (TTM)
3.000High2.565Low1.23MVolume3.000Open2.975Pre Close3.37MTurnover3.88%Turnover RatioLossP/E (Static)54.64MShares5.83052wk High1.99P/B87.36MFloat Cap0.36352wk Low--Dividend TTM31.65MShs Float16.220Historical High--Div YieldTTM14.62%Amplitude0.363Historical Low2.745Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Evexta Bio Appoints Shawn M. Leland as Chairman of the Board of Directors
PARIS--(BUSINESS WIRE)--Evexta Bio SA, a clinical-stage biotechnology company focused on developing first-in-class therapies in oncology, announces the appointment of Shawn M. Leland, PharmD, RPh as C
Elevation Oncology Initiated at Overweight by Piper Sandler
Elevation Oncology Initiated at Overweight by Piper Sandler
Express News | Piper Sandler Initiates Coverage On Elevation Oncology With Overweight Rating, Announces Price Target of $10
Express News | Elevation Oncology Inc : Stephens Initiates With Overweight Rating; Price Target $8
Elevation Oncology Initiated at Overweight by Stephens & Co.
Elevation Oncology Initiated at Overweight by Stephens & Co.
Express News | Stephens & Co. Initiates Coverage On Elevation Oncology With Overweight Rating, Announces Price Target of $8
Comments
$Elevation Oncology(ELEV.US$ Data expected readout of EO-3021 data in the latter half of 2024, which could showcase the efficacy and safety of the anti-Claudin 18.2 antibody-drug conjugate in treating advanced cancers.
Furthermore, preclinical data has shown that Elevation Oncology’s HER3-ADC candidate demonstrates significant antitumor activity, suggesting a strong foundation for future clinical evaluations
Furthermore, preclinical data has shown that Elevation Oncology’s HER3-ADC candidate demonstrates significant antitumor activity, suggesting a strong foundation for future clinical evaluations
Hello Mooers! ![]()
A quick recap for the month ending April 30, 2024.
![]()
Ten stocks with >300% YTD
![]()
$Swvl Holdings(SWVL.US$718.40%
![]()
$Root Inc(ROOT.US$564.60%
![]()
$Elevation Oncology(ELEV.US$561.08%
![]()
$JanOne(JAN.US$554.05%
![]()
$GeneDx Holdings(WGS.US$520.71%
![]()
$Corbus Pharmaceuticals(CRBP.US$513.25%
![]()
$AGBA Group(AGBA.US$482.90%
![]()
$Janux Therapeutics(JANX.US$431.22%
![]()
$Dave Inc(DAVE.US$4...
A quick recap for the month ending April 30, 2024.
4
1
$Elevation Oncology(ELEV.US$
NEWS
Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024
Elevation Oncology announces promising preclinical data for its HER3-ADC program, showcasing proof-of-concept results at AACR Annual Meeting 2024. The data demonstrates HER3-dependent cell killing and robust anti-tumor activity in solid tumors with high HER3 expression. The company aims to nominate a development candidate later in 2024.
NEWS
Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024
Elevation Oncology announces promising preclinical data for its HER3-ADC program, showcasing proof-of-concept results at AACR Annual Meeting 2024. The data demonstrates HER3-dependent cell killing and robust anti-tumor activity in solid tumors with high HER3 expression. The company aims to nominate a development candidate later in 2024.
2
$Elevation Oncology(ELEV.US$ $Merrimack Pharmaceuticals(MACK.US$ Merrimack Gets $225 Million Milestone Payment, Schedules Meeting For Dissolution Plan
MT Newswires· 2 mins ago
Merrimack Pharmaceuticals (MACK) said late Wednesday it has received a $225 million milestone payment from Ipsen and called for a special stockholder meeting on May 10 to approve a plan of dissolution.
The milestone payment was due from Ipsen after the US Food and Drug Administration approved Onivyde as a first-line...
MT Newswires· 2 mins ago
Merrimack Pharmaceuticals (MACK) said late Wednesday it has received a $225 million milestone payment from Ipsen and called for a special stockholder meeting on May 10 to approve a plan of dissolution.
The milestone payment was due from Ipsen after the US Food and Drug Administration approved Onivyde as a first-line...
2
2
$Elevation Oncology(ELEV.US$ Elevation Oncology Announced That It Has Expanded Its Ongoing Phase 1 Clinical Trial Of EO-3021 Outside The United States, Dosing The First Patient In Japan
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg